Funding & Fellowship Opportunities


Alzheimer's Drug Discovery Foundation

Deadline: June 26, 2012
Website: http://www.alzdiscovery.org/wp-content/uploads/2011/11/2012-nih_addf-funding-initiative.pdf
Contact: (212) 901-8019, Niyati Thakker, nthakker@alzdiscovery.org

The Alzheimer's Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer's disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation.

American Gastroenterological Association: Takeda Research Scholar Award in Gastroesophageal

Deadline: July 13, 2012
Website: www.gastro.org/researchfunding
Contact: 301-222-4012, awards@gastro.org

This award provides $60,000 per year for two years (total $120,000) to young investigators working toward independent careers in gastroenterology, hepatology, or related areas. This award is limited to research relevant to gastroesophageal reflux disease including Barrett's Esophagus. The overall objective of the Research Scholar Award (RSA) is to enable young investigators to develop independent and productive research careers in digestive diseases by ensuring that a major proportion of their time is protected for research.

2012 Epigenetics Program Project-Multiple Myeloma Research Foundation

Deadline: Ongoing
Website: www.ellisonfoundation.org/index.jsp
Contact: grants@solvingkidscancer.org

The development of new therapies for pediatric cancers with the poorest outcomes is essential to improving survivorship. Solving Kids' Cancer focuses on expanding the menu of therapeutic options to positively impact children in treatment today as well as those diagnosed in the future through clinical studies of novel agents.

In the next two years, more pediatric cancer genomes will be decoded with additional pathways and targets identified. Numerous candidate agents and delivery mechanisms that potentially target these biological discoveries will need to be studied in children to confirm their biologic relevance. The Therapeutic Development Initiative(TDI) is Solving Kids' Cancer's strategic program to support the investigation of novel treatments through clinical studies to answer important research questions as quickly, effectively, and economically as possible.

The TDI utilizes a pre-proposal format called a Clinical Idea of Intent for all submissions that is used to evaluate your proposal's fit with the stated aims and review criteria of the TDI. All submitted Clinical Ideas of Intent will be reviewed through a triage process and those proposals meeting the aims of the program will be requested to submit further proposal details. Proposals can be submitted open-ended throughout the year, keeping in-mind that proposals received earlier have a greater chance of support based on the programming budget.

Solving Kids' Cancers: Therapeutic Development Initiative (TDI) "Clinical Idea of Intent" Request For Proposal

Deadline: Ongoing
Website: www.autismspeaks.org/science/research/grants/open_grants_how_to_apply.php
Contact: (609) 228-7313, Joan New, jnew@autismspeaks.org

Autism Speaks places a high priority on innovation and has designed its new Trailblazer Award to respond quickly to fund highly novel transformative projects. The Trailblazer Award mechanism will support highly novel "out of the box" autism-relevant research that opens new avenues to understanding the causes, diagnosis, subtyping, prevention, treatments, and cure of autism spectrum disorders. The Trailblazer Award mechanism is designed to fund small investigator-initiated high risk/high impact projects that are potentially transformative, paradigm shifting, and/or will overcome significant roadblocks in autism research within a 12 month period. The cattegories are Developmental Disabilities, Environmental Health, Genetics, Basic Research, Cellular/Molecular Biology, Clinical Research and Communication Disorders.

Investigators holding full-time tenured or tenure-track faculty appointments or equivalent full-time non-tenure track appointments at accredited academic, medical or research institutions are eligible to apply. Eligibility must be demonstrated at the time of registration. Applicants who do not meet the eligibility criteria above (e.g., postdoctoral fellows, medical residents, clinical fellows, part-time faculty members, etc.) are eligible to apply only if the Letter of Intent section includes clear documentation from the applicant's institution stating that appointment to a full-time, faculty position will be in effect by the start date of the grant.

Submission of a Letter of Intent page in the online grant system is required. If your LOI is approved, you will be invited to complete the application. The relevance of the proposed research to the Autism Speaks 2010 targeted research priority areas must be explicitly stated. Trailblazer awards are limited to a period of 12 months and an amount up to $100,000.

Michael J. Fox Foundation for Parkinson's Research: Neurotrophic Factor Challenge

Deadline: Rolling basis
Website: http://www.michaeljfox.org/research_fundingOpportunities_program.cfm?SegmentID=2
Contact: research@michaeljfox.org

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) seeks to support work that can accelerate neurotrophic factor therapeutic development for Parkinson’s disease (PD). Applicants may submit a proposal focused on improving current neurotrophic factor approaches by identifying novel neurotrophic factors and delivery methods, as well as providing insight into why neurotrophic factors have not been effective in alpha-synuclein models. Proposals will be considered for a one-year, $125,000 award.

Michael J. Fox Foundation for Parkinson's Research: Dyskinesia Program 2012

Deadline: Rolling basis
Website: http://www.michaeljfox.org/research_fundingOpportunities_program.cfm?SegmentID=2
Contact: research@michaeljfox.org

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) wishes to engage researchers and drug makers focused on studying and/or therapeutically treating levodopa-induced dyskinesia (LID). Applicants may submit a proposal focused on a relevant area of LID research (see full details below) for consideration of a one-year, $125,000 award. See the Special Requirements section below for additional information.                         

Michael J. Fox Foundation for Parkinson's Research: Biomarkers 2012

Deadline: Rolling basis
Website: http://www.michaeljfox.org/research_fundingOpportunities_program.cfm?SegmentID=2
Contact: research@michaeljfox.org

The identification, development, and use of biomarkers to distinguish and track Parkinson’s disease (PD), as well as markers to detect how drugs act in the body, could greatly improve the clinical development of therapies for people with PD. Such biomarkers can inform critical ‘go/no-go’ decisions within companies and ensure that clinical trials, especially trials of potential disease-modifying therapies, provide clearer and more definitive results. Currently, MJFF is sponsoring the Parkinson’s Progression Marker Initiative (PPMI), a five-year, landmark clinical study aiming to identify biomarkers of PD progression.

In 2012, MJFF will focus its efforts on establishing a set of biological samples (blood, CSF, DNA, RNA) and associated clinical data to be made available to the research community at large for biomarker discovery purposes. It is estimated that data and samples will be available in early 2013. MJFF will also continue to support the use of existing bio specimen and tissue resources for biomarker discovery and optimization.

Solving Kids' Cancer's: Therapeutic Development Initiative (TDI) "Clinical Idea of Intent" Request For Proposal

Deadline: Ongoing
Website: www.ellisonfoundation.org/index.jsp
Contact: grants@solvingkidscancer.org

The development of new therapies for pediatric cancers with the poorest outcomes is essential to improving survivorship. Solving Kids' Cancer focuses on expanding the menu of therapeutic options to positively impact children in treatment today as well as those diagnosed in the future through clinical studies of novel agents.

In the next two years, more pediatric cancer genomes will be decoded with additional pathways and targets identified. Numerous candidate agents and delivery mechanisms that potentially target these biological discoveries will need to be studied in children to confirm their biologic relevance. The Therapeutic Development Initiative(TDI) is Solving Kids' Cancer's strategic program to support the investigation of novel treatments through clinical studies to answer important research questions as quickly, effectively, and economically as possible.

The TDI utilizes a pre-proposal format called a Clinical Idea of Intent for all submissions that is used to evaluate your proposal's fit with the stated aims and review criteria of the TDI. All submitted Clinical Ideas of Intent will be reviewed through a triage process and those proposals meeting the aims of the program will be requested to submit further proposal details. Proposals can be submitted open-ended throughout the year, keeping in-mind that proposals received earlier have a greater chance of support based on the programming budget.

Autism Speaks Trailblazer Award Program Organization

Deadline:  Ongoing
Website: www.autismspeaks.org/science/research/grants/open_grants_how_to_apply.php
Contact: (609) 228-7313, Joan New jnew@autismspeaks.org

Autism Speaks places a high priority on innovation and has designed its new Trailblazer Award to respond quickly to fund highly novel transformative projects. The Trailblazer Award mechanism will support highly novel "out of the box" autism-relevant research that opens new avenues to understanding the causes, diagnosis, subtyping, prevention, treatments, and cure of autism spectrum disorders. The Trailblazer Award mechanism is designed to fund small investigator-initiated high risk/high impact projects that are potentially transformative, paradigm shifting, and/or will overcome significant roadblocks in autism research within a 12 month period. The cattegories are Developmental Disabilities, Environmental Health, Genetics, Basic Research, Cellular/Molecular Biology, Clinical Research and Communication Disorders.

Investigators holding full-time tenured or tenure-track faculty appointments or equivalent full-time non-tenure track appointments at accredited academic, medical or research institutions are eligible to apply. Eligibility must be demonstrated at the time of registration. Applicants who do not meet the eligibility criteria above (e.g., postdoctoral fellows, medical residents, clinical fellows, part-time faculty members, etc.) are eligible to apply only if the Letter of Intent section includes clear documentation from the applicant's institution stating that appointment to a full-time, faculty position will be in effect by the start date of the grant.

Submission of a Letter of Intent page in the online grant system is required. If your LOI is approved, you will be invited to complete the application. The relevance of the proposed research to the Autism Speaks 2010 targeted research priority areas must be explicitly stated. Trailblazer awards are limited to a period of 12 months and an amount up to $100,000.